HomepageKLBF • IDX
add
Kalbe Farma Tbk PT
Vorige slotkoers
Rp 935,00
Dag-range
Rp 935,00 - Rp 945,00
Jaar-range
Rp 935,00 - Rp 1.600,00
Beurswaarde
44,00Â bln. IDR
Gem. volume
42,64Â mln.
Koers/winst
11,68
Dividendrendement
3,83%
Primaire beurs
IDX
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (IDR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 9,34Â bln. | 11,29% |
Bedrijfskosten | 2,14Â bln. | -6,07% |
Netto inkomsten | 1,03Â bln. | 19,88% |
Netto winstmarge | 11,07 | 7,68% |
Winst per aandeel | 22,72 | 20,72% |
EBITDA | 1,47Â bln. | 16,93% |
Effectief belastingtarief | 19,41% | — |
Balans
Totale activa
Totale passiva
| (IDR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 4,49Â bln. | -7,83% |
Totale activa | 30,70Â bln. | 4,31% |
Totale passiva | 5,97Â bln. | 23,38% |
Totaal aandelenvermogen | 24,73 bln. | — |
Uitstaande aandelen | 45,29 mld. | — |
Koers-boekwaardeverhouding | 1,82 | — |
Rendement op activa | 10,54% | — |
Rendement op kapitaal | 12,72% | — |
Kasstroom
Nettomutatie in liquide middelen
| (IDR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 1,03Â bln. | 19,88% |
Operationele kasstroom | 1,09Â bln. | -13,06% |
Kasstroom uit beleggingen | -539,88Â mld. | -106,37% |
Kasstroom uit financiering | -265,30Â mld. | 48,97% |
Nettomutatie in liquide middelen | 283,54Â mld. | -48,34% |
Vrije kasstroom | 1,37Â bln. | 21,29% |
Over
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Opgericht
10 sep 1966
Website
Werknemers
12.835